X4 Pharmaceuticals, Inc.

Equities

XFOR

US98420X1037

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-13 pm EDT			5-day change	1st Jan Change
0.9766 ^USD	-6.99%		-18.62%	+16.47%

May. 09	Sector Update: Health Care Stocks Higher Late Afternoon	MT
May. 09	X4 Pharmaceuticals Receives $125 Million Additional Capital; Shares Rise	MT

X4 Pharmaceuticals, Inc. Announces the Resignation of Derek Meisner from His Position as Chief Legal Officer and Corporate Secretary of the Company, Effective August 22, 2022

July 29, 2022 at 04:05 pm EDT

On July 25, 2022, Derek Meisner provided X4 Pharmaceuticals, Inc. (the “Company”) with notice of his intent to resign from his position as Chief Legal Officer and Corporate Secretary of the Company, effective August 22, 2022, in order to pursue another opportunity.

Latest news about X4 Pharmaceuticals, Inc.

Sector Update: Health Care Stocks Higher Late Afternoon	May. 09	MT
X4 Pharmaceuticals Receives $125 Million Additional Capital; Shares Rise	May. 09	MT
X4 Pharmaceuticals, Inc. Draws an Additional Tranche of $20 Million Under Its Existing Loan Facility with Hercules Capital, Inc	May. 09	CI
Transcript : X4 Pharmaceuticals, Inc., Q1 2024 Earnings Call, May 07, 2024	May. 07
X4 Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 07	CI
HC Wainwright Adjusts Price Target on X4 Pharmaceuticals to $5 From $3, Maintains Buy Rating	Apr. 30	MT
Pantherx® Rare Partner with X4 Pharmaceuticals Inc. for the Distribution of Xolremdi? (Mavorixafor), the First FDApproved Therapy Indicated for Use in Patients with Whim Syndrome	Apr. 29	CI
X4 Pharmaceuticals' Xolremdi Approved by FDA For WHIM Syndrome	Apr. 29	MT
Transcript : X4 Pharmaceuticals, Inc. - Special Call	Apr. 29
X4 Pharmaceuticals Gets FDA Approval for Xolremdi Capsules	Apr. 29	DJ
X4 Pharmaceuticals, Inc. Announces FDA Approval of XOLREMDI (mavorixafor) Capsules, First Drug Indicated in Patients with Whim Syndrome	Apr. 29	CI
Transcript : X4 Pharmaceuticals, Inc., Q4 2023 Earnings Call, Mar 21, 2024	Mar. 21
X4 Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	Mar. 21	CI
North American Morning Briefing : Investors -2-	Mar. 21	DJ
North American Morning Briefing : Traders Await -2-	Dec. 13	DJ
B. Riley Downgrades X4 Pharmaceuticals to Neutral From Buy, Adjusts Price Target to $1 From $3	Dec. 12	MT
X4 Pharmaceuticals, Inc. Announces Presentation of Additional Data from Mavorixafor Phase 2 Trial in Chronic Neutropenia at ASH 2023	Dec. 09	CI
Transcript : X4 Pharmaceuticals, Inc., Q3 2023 Earnings Call, Nov 09, 2023	Nov. 09
X4 Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 09	CI
North American Morning Briefing : Traders Await -2-	Nov. 09	DJ
X4 Pharmaceuticals Insider Sold Shares Worth $181,573, According to a Recent SEC Filing	Nov. 03	MT
X4 Pharmaceuticals Insider Sold Shares Worth $168,371, According to a Recent SEC Filing	Nov. 03	MT
X4 Pharmaceuticals Announces FDA Acceptance with Priority Review of U.S. NDA for Mavorixafor in Whim Syndrome	23-10-31	CI
X4 Pharmaceuticals Announces Appoints Veteran R. Keith Woods to Board of Directors	23-10-18	CI
Transcript : X4 Pharmaceuticals, Inc. Presents at Morgan Stanley 21st Annual Global Healthcare Conference 2023, Sep-13-2023 07:30 AM	23-09-13

Chart X4 Pharmaceuticals, Inc.

Duration

Period

More charts

Company Profile

X4 Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing novel therapeutics for the treatment of rare diseases and those with limited treatment options, with a focus on conditions resulting from dysfunction of the immune system. Its lead clinical candidate is mavorixafor, a small-molecule selective antagonist of chemokine receptor CXCR4, that is being developed as an oral, once-daily therapy. It has developed a pipeline of small-molecule, oral antagonists of the chemokine receptor C-X-C receptor type 4 (CXCR4). It has two pre-clinical candidates: X4P-003, a second-generation CXCR4 antagonist designed to have enhanced properties relative to mavorixafor, potentially enabling opportunities in CXCR4-dependent disorders and primary immunodeficiencies, and X4P-002, a CXCR4 antagonist with a distribution profile and a demonstrated ability to cross the blood-brain barrier.

Sector

Biotechnology & Medical Research

Calendar

2024-06-10 - Annual General Meeting

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

1.05 USD

Average target price

4.117 USD

Spread / Average Target

+292.11%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
X4 PHARMACEUTICALS, INC.	+16.47%	176M
VERTEX PHARMACEUTICALS INCORPORATED	+5.66%	109B
REGENERON PHARMACEUTICALS, INC.	+11.23%	105B
ARGENX SE	-0.38%	22.25B
BIONTECH SE	-12.15%	22.09B
GENMAB A/S	-7.66%	18.68B
WUXI APPTEC CO., LTD.	-36.52%	17.58B
BEIGENE, LTD.	-10.09%	16.85B
NEUROCRINE BIOSCIENCES, INC.	+3.33%	13.76B
SAREPTA THERAPEUTICS, INC.	+36.58%	12.46B

Bio Therapeutic Drugs